CONSORT diagram (intention-to-treat set). ∗Screen failures due to not meeting eligibility criteria included not having an eligible R/R LBCL histology (n = 6), social/familial/geographical conditions (n = 5), not having PET-positive disease (n = 3), not signing the informed consent form before study procedures (n = 1), not having adequate cardiac function (n = 1), history of cardiovascular condition (n = 1), and receipt of radiation within 6 weeks of leukapheresis (n = 1). †One patient did not meet 2 eligibility criteria (ECOG PS of 0-1 and inadequate renal function). ‡NCP was defined as any CAR T-cell product wherein one of the CD8 or CD4 cell components did not meet 1 of the requirements to be considered liso-cel but could be considered appropriate for infusion. The patient who received NCP (CD8 component was out of specifications) was not included in the safety/efficacy analysis. ECOG PS, Eastern Cooperative Oncology Group performance status; NCP, nonconforming product; PD, progressive disease; PI, principal investigator.